Evotec and Odyssey Therapeutics Partner on AI-Driven Drug Discovery

The partnership integrates Odyssey’s specialized expertise in disease biology with Evotec’s proprietary compound libraries and data-driven screening infrastructure. By applying machine learning to high-throughput experimentation, the companies intend to rapidly identify drug candidates capable of addressing significant unmet medical needs in patients suffering from chronic inflammatory conditions.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, noted that the initiative highlights the necessity of merging deep biological insight with computational discovery tools. Under the terms of the agreement, Evotec will receive milestone payments tied to the successful delivery of validated hit series for specific targets. While the companies did not disclose the specific financial terms of the deal, the collaboration reinforces Evotec’s broader strategy of providing integrated R&D services to biotech partners to shorten the time from research concept to therapeutic development.